Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia

Table 1

Demographic data and other characteristics of the patients.

	Total	Smoking	Nonsmoking
N	98	46	52
Sex = Male (N)	76	37	39
Age (years)^b	39 (20-68)	40 (24-67)	37 (20-68)
Weight (kg)^b	78 (48-137)	78 (48-120)	80 (57-137)
BMI (kg/m^2)^b	26 (15-43)	26 (15-42)	27 (21-43)
Dose (mg/day)^b	350 (150-700)	350 (150-700)	400 (200-650)
Caffeine (N)	75	38	37
Valproic acid (N)	37	14	23
Antidepressants (N)	28	14	14
Benzodiazepines (N)	41	16	25
Mean CZP(ng/mL)^a	421 (262)	382 (269)	462 (212)
Mean NCZP (ng/mL)^a	275 (180)	293 (160)	261 (156)
CZP/NCZP^a	2.00 (1.55)	1.64 (1.25)	2.30 (1.20)
	Leponex	Luverina
N	81	90
Sex = Male (N)	63	68
Age (years)^b	38 (20-67)	39 (22-68)
Weight (kg)^b	77 (48-136)	82 (54-137)
BMI ( kg/m^2)^b	26 (15-43)	27 (18-43)
Dose (mg/day)^b	400 (200-600)	350 (150-700)
Caffeine (N)	62	62
Valproic acid (N)	28	32
Antidepressants (N)	23	28
Benzodiazepines (N)	35	37
Mean CZP (ng/mL)^a	432 (264)	412 (261)
Mean NCZP (ng/mL)^a	294 (185)	258 (175)
CZP/NCZP^a	2.04 (1.66)	1.97 (1.45)

^aExpressed as mean (standard deviation). ^bExpressed as median (range). N: number of patients.